We are back this week with Tom Powles & Brian Rini, MD diving into metastatic RCC!

We discuss risk stratification, their differing opinions around cytoreductive nephrectomy, 1L tx & sequencing, pearls regarding sarcomatoid, non-clear-cell RCC & tips for trainees Uromigos

Fun PrecisCa meeting leaders and innovators in oncology and presenting a complex case on castrate resistant metastatic prostate cancer🤓🔬 #Oncology #cancer #prostatecancer #guoncology

Reunion in Chicago for #HOPlive24 counting down the days to #ASCO24 . Insightful fellow panel on mentorship, educations, career decisions & the job search

#ASCO24 is 4 weeks away! Excited to dive into key studies and their clinical impact at Advancements in Oncology!

InPerson: June 1st, 2024 with Margaret Gatti-Mays MD MPH FACP Dr. Cathy Eng Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation Karine Tawagi MD we will navigate our changing Rx Landscape!

Register: [email protected]…

We are so excited to have the @uromigos back for kidney cancer board review & 2024 updates

First up with Localized RCC discussing risk factors, who needs genetic testing, who qualifies for adjuvant therapy…& who’s a faster swimmer btw Brian Rini, MD & Tom Powles

Very happy to share our study published Journal of Clinical Oncology ! ascopubs.org/doi/full/10.12…

➡️Patients with mUC with NECTIN4 amplifications (occurring in app. 25%) show remarkable responses to single-agent EV, with a 96% objective response rate compared to 32% in non-amplified cases. NECTIN4…

A glimpse of many exciting Med Ed & Professional Dev abstracts to be presented at the ASCO Annual Meeting this year, including 1 oral & 3 posters from our collaboration btw TwoOncDocs & The Fellow On Call

Ronak H. Mistry, DO Samantha Armstrong Karine Tawagi MD Vivek Patel, MD Daniel Hausrath

TwoOncDocs Testicular Cancer Testicular Cancer Canada Testicular Cancer Society Lance Armstrong Indiana University Hematology/Oncology Fellowship HemOnc Today Hem-Onc Fellows Network This is a STAT must listen!

Part 2 of our discussion with the wonderful Dr. Larry Einhorn is out this week covering the Tx of Non-Seminoma including salvage regimens & the TIGER 🐯 trial, toxicities of Tx, as well as words of wisdom for trainees

podcasts.apple.com/us/podcast/two…

KN564: Pembro was approved for high risk adj RCC in Nov 2021 based off this study. Now on NEJM w/ OS benefit.

- DFS HR: 0.72 and OS HR: 0.62
- At 48 mos, OS 91.2% w/ #Pembrolizumab vs 86%
- Toni Choueiri, MD Tian Zhang, MD, MHS Tom Powles et al. 👏👏👏

#OncTwitter #MedTwitter #GUSM

In this week’s episode, Dr. Larry Einhorn discusses the history of testicular cancer Tx, writing board review Qs for the ABIM, treating Lance Armstrong, staging, mediastinal tumors & seminomas

podcasts.apple.com/us/podcast/two…

If AFP is elevated, what is the most likely diagnosis?

April marks #TesticularCancer Awareness Month 💜

We are so excited to welcome Dr. Larry Einhorn from IU Simon Comprehensive Cancer Center, a true legend when it comes to the treatment of Germ Cell Tumors, for our next 2 episodes!

He shares board review pearls & words of wisdom for trainees.

💫📢🎉It’s our immense pleasure to introduce you to the ASCO #IMG CoP - Program Directors Committee. Our goal is to enhance #IMG 's journey and foster a nurturing environment during hem/onc fellowship!

ASCOTECAG Martina Murphy, MD Arthi Sridhar Noha N. Soror, MD, MSc. 𓂀 Karine Tawagi MD OncoAlert

New data from EV302 Enfortumab Vedotin & pembrolizumab for upper tract disease (~25% of pts). UTUC has distinct biological features including more FGFR alterations. PFS & OS HR of 0.50 & 0.53 respectively in the subset is in line with the whole population (0.45 and 0.47) #EAU24

#TDxD now U.S. FDA approved for pan-tumor w/ HER2 IHC3+ solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02:

- Dose 5.4 mg/kg
- Common AE: fatigue,…

Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer) show that ctDNA-ve patients (n=171) with a minimum of 12months follow up have 10% relapse rates and almost no deaths #EAU24 . Do we need to give adjuvant therapy to those as such low risk?

With Matt Galsky #EAU24 adjuvant nivolumab in bladder ca: HR 0.76 in ITT & 0.56 in PD-L1 +ve. Clinically meaningful results especially in PD-L1 +ves. No data on PD-L1-ve! OS is not yet significant but this data is impressive. ~60% relapse and 24% get subsequent IO. ~10% ⬆️tox.

Excited to welcome those in the Chicago area to the next GU Rounds Ivy Room Chicago!

Jam packed agenda +dinner w/ exciting cross-disciplinary discussions in prostate, bladder, renal cancers.

Still a few spots left to sign up @ gurounds.com for this April 3 CME event

Sia Daneshmand, MD, and Karine Tawagi, MD, join Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for non–muscle-invasive bladder cancer. #blcsm | Oncology Brothers Sia Daneshmand, M.D. Karine Tawagi MD

cancernetwork.com/view/treatment…

Oncology Brothers Karine Tawagi MD Sia Daneshmand, M.D. CancerNetwork® Bijoy Telivala Yakup Ergün Andrea Apolo, M.D. Santhosh Ambika Amanda Nizam, MD Petros Grivas Shilpa Gupta Enrique Grande Tom Powles Paulo G Bergerot Very nice, although please note radical cystectomy is not the only standard of care for MIBC. It’s just that we’re biased towards surgery in the USA. Bladder preservation is also NCCN category 1 and should not be biased towards frail.